Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
24.16
+0.16 (0.67%)
At close: Nov 6, 2026, 4:00 PM EST
24.20
+0.04 (0.17%)
After-hours: Nov 6, 2026, 7:58 PM EST
Veracyte Revenue
Veracyte had revenue of $151.75M in the quarter ending September 30, 2026, with 15.08% growth. This brings the company's total for the last twelve months to $581.78M, up 17.50% year-over-year. In the year 2025, Veracyte had annual revenue of $517.15M with 16.01% growth. That makes Veracyte the 10,420th largest company in the world by revenue and 2,205th in the United States.
Revenue (ttm)
$581.78M
Revenue Growth
+17.50%
P/S Ratio
3.35
Revenue / Employee
$770,572
Employees
755
Market Cap
1.95B
Revenue by Geography
- United States 496.60M 96.0%
- International 20.55M 4.0%
Fiscal year ended Dec 31, 2025 See the full Veracyte breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 517.15M | 71.38M | 16.01% |
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
| Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
| Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
| Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
| Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
| Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
| Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
| Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
| Dec 31, 2011 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sotera Health Company | 1.23B |
| NeoGenomics | 787.75M |
| OPKO Health | 654.10M |
| CareDx | 497.40M |
| GeneDx Holdings | 454.43M |
| BillionToOne | 436.87M |
| Castle Biosciences | 377.13M |
| Adaptive Biotechnologies | 298.01M |
VCYT News
- 2 days ago - VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte - PRNewsWire
- 3 days ago - Veracyte falls -54.1% - TheFly
- 3 days ago - Veracyte falls -57.7% - TheFly
- 3 days ago - Veracyte downgraded to Market Perform from Outperform at Leerink - TheFly
- 3 days ago - Veracyte reports Q3 EPS 51c, consensus 41c - TheFly
- 3 days ago - Veracyte narrows FY26 revenue view to $590M-$593M from $590M-$596M - TheFly
- 3 days ago - Veracyte Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Veracyte Earnings release: Q3 2026 - Filings